CN102746388B - 一种链球菌保护性抗原C5a及其制备方法 - Google Patents
一种链球菌保护性抗原C5a及其制备方法 Download PDFInfo
- Publication number
- CN102746388B CN102746388B CN201210225210.1A CN201210225210A CN102746388B CN 102746388 B CN102746388 B CN 102746388B CN 201210225210 A CN201210225210 A CN 201210225210A CN 102746388 B CN102746388 B CN 102746388B
- Authority
- CN
- China
- Prior art keywords
- rscpz
- sez
- restriction enzyme
- mice
- protective antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101710194807 Protective antigen Proteins 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 241000194017 Streptococcus Species 0.000 title abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 20
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 20
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 20
- 241000894006 Bacteria Species 0.000 claims description 24
- 230000012447 hatching Effects 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 abstract description 35
- 241000699670 Mus sp. Species 0.000 abstract description 22
- 238000004458 analytical method Methods 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 239000000427 antigen Substances 0.000 abstract description 4
- 102000036639 antigens Human genes 0.000 abstract description 4
- 108091007433 antigens Proteins 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 230000001681 protective effect Effects 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 238000010367 cloning Methods 0.000 abstract description 2
- 238000002255 vaccination Methods 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 34
- 230000001580 bacterial effect Effects 0.000 description 15
- 239000013642 negative control Substances 0.000 description 14
- 239000013641 positive control Substances 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 230000002103 transcriptional effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000002574 poison Substances 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 101710082751 Carboxypeptidase S1 homolog A Proteins 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 229940031551 inactivated vaccine Drugs 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IDATZUYVZKJKRE-SXMXEBDWSA-N (2s)-2-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan Chemical compound C([C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(N)=O)C1=CC=C(O)C=C1 IDATZUYVZKJKRE-SXMXEBDWSA-N 0.000 description 4
- 101800004967 Small cardioactive peptide B Proteins 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000008126 dulcin Substances 0.000 description 3
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010061372 Streptococcal infection Diseases 0.000 description 2
- 241000194048 Streptococcus equi Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 229960002203 tilactase Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010078546 Complement C5a Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210225210.1A CN102746388B (zh) | 2012-07-02 | 2012-07-02 | 一种链球菌保护性抗原C5a及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210225210.1A CN102746388B (zh) | 2012-07-02 | 2012-07-02 | 一种链球菌保护性抗原C5a及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102746388A CN102746388A (zh) | 2012-10-24 |
CN102746388B true CN102746388B (zh) | 2014-06-25 |
Family
ID=47026923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210225210.1A Expired - Fee Related CN102746388B (zh) | 2012-07-02 | 2012-07-02 | 一种链球菌保护性抗原C5a及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102746388B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105056223B (zh) * | 2015-08-04 | 2018-11-27 | 北京万岁军经贸发展有限公司 | 一种抑制和/或预防a型链球菌感染的联合疫苗 |
CN106008680A (zh) * | 2016-05-27 | 2016-10-12 | 佛山科学技术学院 | 一种链球菌保护性抗原sap及其制备方法 |
CN107286225A (zh) * | 2017-05-26 | 2017-10-24 | 湖北大学 | 一种马链球菌兽疫亚种保护性抗原map及其制备方法 |
CN107129526A (zh) * | 2017-05-26 | 2017-09-05 | 湖北大学 | 一种马链球菌兽疫亚种保护性抗原szo_430及其制备方法 |
CN107353329A (zh) * | 2017-05-26 | 2017-11-17 | 湖北大学 | 一种马链球菌兽疫亚种保护性抗原Sec_205及其制备方法 |
CN107129527B (zh) * | 2017-05-26 | 2020-05-22 | 湖北大学 | 一种马链球菌兽疫亚种保护性抗原hp0623及其制备方法 |
CN111499702B (zh) * | 2020-05-07 | 2021-04-06 | 山东畜牧兽医职业学院 | 一种马链球菌兽疫亚种的检测试剂盒及检测方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679929A (zh) * | 1998-12-07 | 2005-10-12 | 明尼苏达大学董事会 | 链球菌C5a肽酶疫苗 |
-
2012
- 2012-07-02 CN CN201210225210.1A patent/CN102746388B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679929A (zh) * | 1998-12-07 | 2005-10-12 | 明尼苏达大学董事会 | 链球菌C5a肽酶疫苗 |
Non-Patent Citations (4)
Title |
---|
B族链球菌C5a肽酶表位的预测、分段表达及其免疫原性;岳丽琴 等;《中国生物制品学杂志》;20100531;第23卷(第5期);460-465 * |
岳丽琴 等.B族链球菌C5a肽酶表位的预测、分段表达及其免疫原性.《中国生物制品学杂志》.2010,第23卷(第5期),460-465. |
崔健扬.马链球菌兽疫亚种的保护性抗原SzP蛋白的鉴定与评价.《广东畜牧兽医科技》.2012,第37卷(第3期),30-33. |
马链球菌兽疫亚种的保护性抗原SzP蛋白的鉴定与评价;崔健扬;《广东畜牧兽医科技》;20120618;第37卷(第3期);30-33 * |
Also Published As
Publication number | Publication date |
---|---|
CN102746388A (zh) | 2012-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102746388B (zh) | 一种链球菌保护性抗原C5a及其制备方法 | |
Yu et al. | Characterization of a c-type lysozyme of Scophthalmus maximus: expression, activity, and antibacterial effect | |
CN101490083A (zh) | 小化脓性链球菌抗原及其用途 | |
Ko et al. | Molecular characterization, transcriptional profiling, and antibacterial potential of G-type lysozyme from seahorse (Hippocampus abdominalis) | |
CN109536507A (zh) | 布氏鲳鲹抗菌肽基因及其编码的肽和原核表达制备方法 | |
CN102746389A (zh) | 一种链球菌粘附性抗原gapdh及其制备方法 | |
CN106008680A (zh) | 一种链球菌保护性抗原sap及其制备方法 | |
CN104098700B (zh) | 结核分枝杆菌融合蛋白eammh、其构建、表达和纯化方法及其应用 | |
CN106279431B (zh) | 一种猪圆环病毒亚单位灭活疫苗 | |
CN109627316A (zh) | 草鱼IFN-γ2基因及其编码的重组蛋白和应用 | |
Scarpa et al. | Relationship between virulence factor genes in bovine Staphylococcus aureus subclinical mastitis isolates and binding to anti-adhesin antibodies | |
CN103421832A (zh) | 包含氟苯尼考耐药基因蛋白的卵黄抗体及制备与应用 | |
CN104961811A (zh) | 嗜水气单胞菌外膜蛋白基因原核表达蛋白及其应用 | |
Mahan et al. | Neutralization of bovine Concanavalin‐AT cell supernatant‐mediated anti‐Cowdria ruminantium activity with antibodies specific to Interferon gamma but not to tumor necrosis factor | |
CN104211804A (zh) | 一种抗金黄色葡萄球菌多克隆抗体的制备与应用 | |
CN110714000A (zh) | 一种Toll样受体配体蛋白在抗细菌感染中的应用 | |
CN105753949B (zh) | 一种红斑丹毒丝菌抗原蛋白及应用 | |
CN107129527B (zh) | 一种马链球菌兽疫亚种保护性抗原hp0623及其制备方法 | |
CN111053890B (zh) | 来源于鳜鱼的半乳糖凝集素-8在制备抑菌剂中的应用 | |
CN101906166B (zh) | 一种链球菌重组亚单位疫苗及其制备方法 | |
CN105056223B (zh) | 一种抑制和/或预防a型链球菌感染的联合疫苗 | |
CN105254719B (zh) | 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗 | |
CN107670023A (zh) | V12cbd蛋白及其编码基因的一种新用途 | |
CN102977214B (zh) | 用于耐甲氧西林金黄色葡萄球菌(mrsa)疫苗的重组蛋白hf2及制备方法和应用 | |
CN107353329A (zh) | 一种马链球菌兽疫亚种保护性抗原Sec_205及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170710 Address after: 511494, Tian An technology development building, Panyu energy saving Science Park, No. 555 Panyu Avenue, east ring street, 620-621, Guangdong, Guangzhou, Panyu District Patentee after: IPIG Management & Consulting Co., Ltd. Address before: 510275 Xingang West Road, Guangdong, Guangzhou, No. 135, No. Co-patentee before: IPIG Management & Consulting Co., Ltd. Patentee before: Sun Yat-sen University |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140625 Termination date: 20210702 |
|
CF01 | Termination of patent right due to non-payment of annual fee |